New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

  • Study

    Phase II, multicenter, single-arm study (STATICE)
    Pretreated advanced or recurrent HER2-expressing UCS
    Trastuzumab Deruxtecan: HER 2:1+ (low group, n=10) vs. HER 22+ (high group, n=22)


  • Efficacy

    ORR: 68% vs. 54.5% (low and high group, respevtively)
    DoR: 8.1 vs. 6.9 mos
    mPFS: 6.7 vs. 6.2 mos
    mOS: NR vs. 13.3 mos

  • Safety

    Any grade: Nausea (84.55), anemia (54.5%), leucopenia (51.5%), neutropenia (48%)
    Grade≥3 AEs: Anemia (24.2%), neutropenia (21.2%), hypoalbuminemia (12.1%)



    • J Clin Oncol 2023; 28 MAR

    Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

    http://doi.org/10.1200/JCO.22.02558

    Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag